The Motley Fool Previous Page

3 Humongous Health-Care Stocks This Week

Keith Speights
December 14, 2012

Santa came early for some investors. Several health-care stocks took a sleigh ride up the charts. Here are three of the most humongous performers over the past week.

Giddy from Gilead
If you owned shares in YM Biosciences (NYSEMKT: YMI  ) , you're undoubtedly giddy right now. Gilead Sciences (Nasdaq: GILD  ) announced a buyout of the small company for $510 million. YM Biosciences shares shot up nearly 78% for the week on the news.

With the deal, Gilead picks up YM's JAK inhibitor CYT387. The drug showed solid results in a phase 1/2 study targeting treatment of myelofibrosis. Gilead plans to launch a phase 3 trial in 2013 following completion of the acquisition.

Gilead already has its own drug, GS6624, in a phase 2 study for treating myelofibrosis. Unlike YM's CYT387, GS6624 works by attaching to cancer cells and marking them in a way that makes it easier for the body's immune system to attack the cancer. With two drugs taking different approaches, Gilead could emerge at some point as the leader in the myelofibrosis market.

Up early
Infinity Pharmaceuticals (Nasdaq: INFI